Product Images Rivastigmine Transdermal System
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 18 images provide visual information about the product associated with Rivastigmine Transdermal System NDC 63629-2064 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Label - lbl636292064
This text provides instructions and information for the NILD Rivastigmine Transdermal System. Each system contains 27 mg of Rivastigmine and provides 13.3 mg every 24 hours. It is recommended to store the system at 25°C, and one patch should be worn at a time and changed every 24 hours. The patch should be applied to intact skin and should not be cut. Additionally, the patch should be kept out of reach of children and is for transdermal use only. The text also includes the NDC code and branding information for the product.*
Chemical Structure - rivastigmine 01
Figure 1 - rivastigmine 02
Layer 1, Layer 2, Layer 3, and Layerd are mentioned, along with the repeated word "Dimple." No further information is available to provide a useful description.*
Figure 2 - rivastigmine 03
The text represents the concentration of Rivastigmine in ng/mL for three groups with different dosages: 13.3 mg/24 hours (n = 19), 9.5 mg/24 hours (n = 22), and 4.6mg/24 hours (n = 22). There is no other information available in the text.*
Figure 3 - rivastigmine 04
Figure 4 - rivastigmine 05
Figure 5 - rivastigmine 06
Figure 6 - rivastigmine 07
Figure 7 - rivastigmine 08
The text appears to be reporting the results of a study on the effectiveness of a medication called Rivastigmine Transdermal System. The table shows LS mean differences and improvement percentages for weeks 8, 16, and 24 of treatment, along with p-values indicating statistical significance. The medication was tested using two different dosages: 15 cm² and 5 cm².*
Figure 8 - rivastigmine 09
This is a brief report of clinical trial results comparing the 5 and 15 cm² patches of the Rivastigmine Transdermal System after 8, 16, and 24 weeks of treatment. The analysis is based on LS means and their standard errors using a statistical model adjusted for pooled center and baseline measurements. The table shows the LS mean improvements in the cognitive function scores and their corresponding p-values, which suggest a significant difference only for the 16 weeks follow-up time.*
Figure A - rivastigmine 10
Figure B - rivastigmine 11
Figure C - rivastigmine 12
Figure D - rivastigmine 13
Protective liners are typically used to cover and protect surfaces from damage, scratches or contamination. The given text seems to only contain partial words and is not available for generating a meaningful description.*
Figure E - rivastigmine 14
Figure F - rivastigmine 15
Figure G - rivastigmine 16
Figure H - rivastigmine 17
This text provides instructions for disposing of a slide folded patch. It advises folding the sticky sides of the patch together and placing it in the trash. The text also recommends keeping the folded patch away from children and pets.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.